Capbio (300639.SZ): 2023 net profit of 140 million yuan, plans to distribute 10 to 0.65 yuan
On April 23, Ge Longhui (300639.SZ) announced its 2023 annual report. Operating revenue for the reporting period was 1.04 billion yuan, down 80.27% year on year; net profit attributable to shareholders of listed companies was 140 million yuan, down 91.86% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 113 million yuan, down 93.47% year on year; it plans to distribute a cash dividend of 0.65 yuan (tax included) for every 10 shares to all shareholders.
Betta Pharmaceuticals revealed behind the layoffs: last year's profit did not increase revenue, R&D personnel fell 13%
The 2023 financial report shows that there is a phenomenon where profit increases do not increase revenue, and management expenses have dropped sharply. Some industry insiders questioned that layoffs and lower management expenses increased their current profits, but the sustainability of this method needs to be considered.
Centre Testing International Buys Back Shares for 72 Million Yuan
Centre Testing International Group (SHE:300012) repurchased shares for 71.5 million yuan, the company said in a Tuesday filing on the Shenzhen Stock Exchange. The Chinese testing laboratory company bo
Express News | Pearl Group: Net profit from mother for the first quarter was 608 million yuan, up 4.45% year on year
Meikang Biotech (300439.SZ): Net profit of 79.968 million yuan in the first quarter increased 10.76% year-on-year
Gelonghui, April 23 | Meikang Biotech (300439.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 482 million yuan, down 1.91% year on year; net profit attributable to shareholders of listed companies was 79.968 million yuan, up 10.76% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 64.749 million yuan, up 14.37% year on year; basic earnings per share were 0.21 yuan.
Ed Biotech (300685): Performance has achieved steady growth, and the new product layout is expected to accelerate
Event: The company publishes its report for the first quarter of 2024. In the first quarter of 2024, the company achieved operating income of 233 million yuan, a year-on-year increase of 19.53%; realized net profit to mother of 64 million yuan, an increase of 12.01 million yuan over the previous year